Products
Fenofibric acid was approved in many countries in 2013 in sustained-release capsule form (Trilipix). The capsules are not commercially available.
Structure and properties
Fenofibric acid (C17H15ClO4, Mr = 318.8 g/mol) is present in the drug as the choline salt (choline fenofibrate), a white to yellow powder that is very soluble in water. Fenofibric acid is the active ingredient of fenofibrate. Fenofibric acid, unlike fenofibrate, is not a prodrug.
Effects
Fenofibric acid (ATC C10AB11) has lipid-lowering properties. It lowers cholesterol and triglycerides and increases HDL. The effects are due to activation of nuclear receptors PPARα (Peroxisome Proliferator Activated Receptors). PPAR regulate genes that play important roles in lipid and glucose metabolism. The half-life is approximately 20 hours.
Indications
For the treatment of dyslipidemia (hypertriglyceridemia, mixed hyperlipidemia).
Dosage
According to the SmPC. Capsules are taken once daily, independent of meals.
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include indigestion and increased liver enzymes. Fenofibric acid may make the skin sensitive to the sun.
